FROM MOLECULE...TO HUMAN
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Researchers from the I2BC (SB2SM), in collaboration with CNRS (LCP, ICMMO) have designed an original artificial photosynthesis approach, based on the use of semiconductor nanopolymers composed of PolyDiPhenylButadiyne, capable of reproducing the full photo-redox reaction of plant Photosystem II, that is the production of O2 by photo-oxidation of water and the reduction of a quinone.
Researchers from the LMC have developed a new series of iminosydnones that can split in two and release two fluorophores. They are providing a proof of concept that this "click and release" reaction can be triggered in living cells.
SIMoS researchers, in collaboration with Genopole, Excellgene, Vaxeal holding SA (Switzerland), used a large-scale approach to map and characterize the response of CD4 T-cells from healthy donors, against two proteins from the Ebola-Zaire virus. They observed a strong response to the viral nucleoprotein (NP) and suggest that components of NP may be included in the design of new Ebola vaccines.
An opinion article, published in Environmental Microbiology, and written by an international consortium initiated by three researchers of Joliot Institute, proposes an original way of research on Covid-19 through the identification by sequencing of attenuated variants of the SARS-CoV-2 virus in populations at risk with little or no symptoms.
In order to answer this question, a vast study of experimental psychology and chronobiology, directed by Virginie Van Wassenhove (NeuroSpin) was launched in collaboration with Inserm and the University of Paris-Saclay.
The European Commission once more places its trust on Multiwave company and its partners, Aix-Marseille Université1, CEA2 and Université Catholique de Louvain to revolutionize ultra-high field magnetic resonance imaging of the brain.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.